IRIS Refocusing Energies On Urinalysis Market With Model 939 System
This article was originally published in The Gray Sheet
Executive Summary
The first move by International Remote Imaging Systems (IRIS) in shifting its primary emphasis to the urinalysis market will be the launch of the Model 939 fully automated lab system immediately following expected 510(k) clearance at the end of the month.
You may also be interested in...
In Brief: IRIS/PSI
IRIS/PSI: International Remote Imaging Systems completes acquisition of the digital imaging business of Perceptive Scientific Instruments for $9.1 mil. in cash, a $7 mil. debenture, and "a five year warrant to purchase 875,000 shares of IRIS common stock at $8" each. A letter of intent for the deal was announced in the spring ("The Gray Sheet" May 13, In Brief)...
IRIS positioning The White Iris white blood cell analyzer as replacement for manual microscopy.
IRIS WILL ENTER HEMATOLOGY TESTING FIELD WITH THE WHITE IRIS, an automated high-speed leukocyte differential analyzer designed to classify normal, immature, and other abnormal white blood cells. Cleared through the 510(k) process May 13, The White Iris is scheduled for a late third-quarter limited roll-out to a number of "strategic" locations in the U.S., International Remote Imaging Systems says.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”